KRAS mutation status, comorbidity, and mortality in patients with metastatic colorectal cancer in Denmark

Acta Oncol. 2018 Dec;57(12):1727-1729. doi: 10.1080/0284186X.2018.1503420. Epub 2018 Sep 28.

Authors

Anne Gulbech Ording¹, Buket Öztürk¹, Karen-Lise Garm Spindler^{2

3}, Henrik Toft Sørensen¹, Margaret McCusker⁴, Vera Ehrenstein¹

Affiliations

¹ a Department of Clinical Epidemiology , Aarhus University Hospital , Aarhus , Denmark.
² b Department of Experimental Clinical Oncology , Aarhus University Hospital , Aarhus , Denmark.
³ c Department of Oncology , Aarhus University Hospital , Aarhus , Denmark.
⁴ d Diagnostics Information Solutions , F Hoffmann-La Roche AG , Pleasanton , CA , USA.

PMID: 30264648
DOI: 10.1080/0284186X.2018.1503420

No abstract available

Publication types

Letter

MeSH terms

Adult
Colorectal Neoplasms* / epidemiology
Colorectal Neoplasms* / genetics
Colorectal Neoplasms* / pathology
Comorbidity
DNA Mutational Analysis
Denmark / epidemiology
Female
Follow-Up Studies
Humans
Male
Mortality
Mutation*
Neoplasm Metastasis
Proto-Oncogene Proteins p21(ras) / genetics*

Substances

KRAS protein, human
Proto-Oncogene Proteins p21(ras)